Document Detail

Frequency of expression of RHAMM/CD168 in Egyptian patients with CML.
MedLine Citation:
PMID:  21057560     Owner:  NLM     Status:  MEDLINE    
WE AIMED: at studying the frequency of expression of RHAMM/CD168 in Egyptian patients with CML, both in chronic phase and accelerated/blastic phase, as a potential target structure for cellular immunotherapies, and to compare it with available western records.
PATIENTS AND METHODS: RHAMM expression was tested by RT-PCR in peripheral blood mononuclear cells of 60 CML patients divided into 2 groups, group A: 44 chronic phase CML patients, group B: 16 accelerated/ blastic phase patients as well as 15 healthy volunteers.
OUR RESULTS: Demonstrated that 14/44 (31.8%) of chronic CML patients showed positive RHAMM expression in contrast to 15/16 ( 93.7%) in the accelerated/blastic phase patients. Moreover within the chronic phase patients the RHAMM positive patients had a significantly higher level of bcr-abl/abl ratio. This highlighted the contribution of RHAMM expression with CML disease progression.
CONCLUSION: Our work demonstrated a similar proportion of RHAMM expression in both Egyptian and western CML patients. This may pave the way for subsequent studies suggesting the concomitant use of RHAMM R3 peptide vaccination with conventional CML therapy especially in accelerated phase, in order to achieve complete molecular remission for our patient.
Heba M Gouda; Mohsen M Abdel Mohsen
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Journal of the Egyptian National Cancer Institute     Volume:  21     ISSN:  1110-0362     ISO Abbreviation:  J Egypt Natl Canc Inst     Publication Date:  2009 Jun 
Date Detail:
Created Date:  2010-11-08     Completed Date:  2011-02-24     Revised Date:  2013-07-15    
Medline Journal Info:
Nlm Unique ID:  9424566     Medline TA:  J Egypt Natl Canc Inst     Country:  Egypt    
Other Details:
Languages:  eng     Pagination:  93-9     Citation Subset:  IM    
The Department of Clinical & Chemical Pathology, Cairo University, Egypt.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antigens, CD44 / genetics*
Blast Crisis
Case-Control Studies
Cell Proliferation*
Extracellular Matrix Proteins / genetics*
Fusion Proteins, bcr-abl / genetics
Leukemia, Myeloid, Chronic-Phase / blood,  genetics*
Middle Aged
RNA, Messenger / genetics
RNA, Neoplasm / genetics
Reverse Transcriptase Polymerase Chain Reaction
Tumor Markers, Biological / genetics*
Reg. No./Substance:
0/Antigens, CD44; 0/Extracellular Matrix Proteins; 0/Fusion Proteins, bcr-abl; 0/RNA, Messenger; 0/RNA, Neoplasm; 0/Tumor Markers, Biological; 0/hyaluronan-mediated motility receptor

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Expression profile of apoptotic mediators and proliferative markers in oral squamous cell carcinoma.
Next Document:  Cytokine gene polymorphisms in egyptian cases with brain tumors.